Compare CVS Health Corp (CVS) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? CVS Health Corp trades at $93.57 (market cap $119.58B), while GraniteShares 2x Long NVDA Daily ETF trades at $34.94. The key difference: CVS Health Corp pays a 2.84% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals.
| CVS | NVDL | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $110.60 | $43.02 |
52-Week Low | $65.51 | $21.76 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
